Analysis of circulating tumor cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial

被引：0
|
作者：
Vogelzang, N. J. [1 ,2 ]
Petrylak, D. P. [3 ]
Fizazi, K. [4 ]
Sternberg, C. N. [5 ,6 ]
De Wit, R. [7 ]
Liu, K. [8 ]
Waldman, M. [8 ]
Barton, D. [8 ]
Jungnelius, U. [8 ]
Fandi, A. [8 ]
机构：
[1] US Oncol Res, Houston, TX USA
[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[3] Yale Canc Ctr, Dept Med, Div Oncol, New Haven, CT USA
[4] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[5] San Camillo Hosp, Dept Med Oncol, Rome, Italy
[6] Forlanini Hosp, Dept Med Oncol, Rome, Italy
[7] ErasmusMC Canc Inst, Rotterdam, Netherlands
[8] Celgene Corp, Summit, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA23
引用
下载
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [1] Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer
    Vogelzang, Nicholas J.
    Fizazi, Karim
    Burke, John M.
    De Wit, Ronald
    Bellmunt, Joaquim
    Hutson, Thomas E.
    Crane, Edward
    Berry, William R.
    Doner, Kevin
    Hainsworth, John D.
    Wiechno, Pawel J.
    Liu, Kejian
    Waldman, Michelle F.
    Gandhi, Anita
    Barton, Debora
    Jungnelius, Ulf
    Fandi, Abderrahim
    Sternberg, Cora N.
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2017, 71 (02) : 168 - 171
  • [2] Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC)
    Punnoose, Elizabeth
    Tucker, Eric
    Marrinucci, Dena
    Amler, Lukas C.
    Koeppen, Hartmut
    Patel, Premal H.
    Yan, Yibing
    Riisnaes, Ruth
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from castrate-resistant prostate cancer (CRPC) patients
    Punnoose, Elizabeth
    Tucker, Eric
    Szafer-Glusman, Edith
    Zhu, Jin
    Marrinucci, Dena
    Louw, Jessica
    Lee, Florence
    Kitchen, Mikel
    Bales, Natalee
    Amler, Lukas
    Koeppen, Hartmut
    Patel, Premal
    Yan, Yibing
    Riisnaes, Ruth
    Attard, Gerhardt
    de Bono, Johann
    CANCER RESEARCH, 2014, 74 (19)
  • [4] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC)
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] C11-acetate PET for docetaxel prednisone (DP) response assessment in castrate-resistant prostate cancer (CRPC).
    Sharma, Nancy
    Menda, Yusuf
    Boles-Ponto, Laura
    Vaena, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Phase I Trial of the Combination of Docetaxel Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
    Thakur, Manish K.
    Heilbrun, Lance
    Dobson, Kimberlee
    Boerner, Julie
    Stark, Karri
    Li, Jing
    Smith, Daryn
    Heath, Elisabeth
    Fontana, Joseph
    Vaishampayan, Ulka
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E695 - E703
  • [7] Feasibility of multimodal molecular characterization of the androgen receptor (AR) in circulating tumor cells (CTCs) from patients with castrate-resistant prostate cancer (CRPC).
    VanderWeele, David James
    Isikbay, Masis
    Reyes, Edwin
    Duggan, Ryan
    Wyche, Alicia J.
    Stadler, Walter Michael
    Vander Griend, Donald
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] Phase II trial of cediranib (AZD 2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P.
    Mulquin, M.
    Wright, J.
    Turkbey, I. B.
    Choyke, P.
    Ahlers, C. M.
    Figg, W. D.
    Dahut, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [9] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Combination of a polyamine-free oral nutritional supplement (ONS) with docetaxel in castrate-resistant prostate cancer (CRPC) patients (pts): A phase II trial
    Artignan, Xavier
    Miglianico, Laurent
    Bligny, Dominique
    Abraham, Christine
    Moulinoux, Jacques Philippe
    Cipolla, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345